CALCITONIN-SALMON (calcitonin salmon) by Fresenius Kabi is calcitonin-salmon is a calcitonin receptor agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 2 more indications. First approved in 2024.
Drug data last refreshed 21h ago
Calcitonin-salmon is a calcitonin receptor agonist. Calcitonin-salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency…
Calcitonin
Worked on CALCITONIN-SALMON at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.